Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 18:2018:4721505.
doi: 10.1155/2018/4721505. eCollection 2018.

What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT

Affiliations

What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT

Rafiyah Khan et al. Mult Scler Int. .

Abstract

Background: Multiple Sclerosis (MS) is a chronic neurological disorder caused by neurodegeneration within the central nervous system. It results in impaired physical, cognitive, and psychological functioning and can also lead to lower urinary tract symptoms including nocturia. While clinical trials have suggested an association between nocturia and melatonin secretion, to our knowledge, no qualitative research has been conducted on the experience of taking melatonin to treat nocturia in progressive MS within a clinical trial.

Methods: 17 semistructured qualitative interviews were conducted as part of a double-blind, randomised, placebo controlled, crossover, clinical trial with consenting adults with MS. Interviews explored participants' experiences of nocturia associated with MS and their experience of taking melatonin as a trial treatment for nocturia versus a placebo. Data was analysed using a thematic analysis.

Results: Themes on the experience of nocturia revealed participants' understandings of nocturia, the impact it had on their night, and increased daily fatigue. Themes on the intervention showed perceived improvements to nocturia, sleep, and energy and negative effects including lethargy, a lack of significant change, and physical side effects including vivid dreams.

Conclusion: This qualitative exploration revealed an association between nocturia and increased levels of fatigue during the day by those with MS. However, perspectives towards the effectiveness of melatonin as a potential treatment varied as both placebo and melatonin were perceived as having very similar effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of qualitative themes and subthemes.
Box 1
Box 1
Topic guide for qualitative interviews.

References

    1. MS Society. MS in the UK. https://www.mssociety.org.uk/sites/default/files/MS%20in%20the%20UK%20Ja.... January 2016. Accessed November, 2017.
    1. Zecca C., Riccitelli G. C., Disanto G., et al. Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients’ quality of life. European Journal of Neurology. 2016;23(7):1228–1234. doi: 10.1111/ene.13010. - DOI - PubMed
    1. Brucker B. M., Nitti V. W., Kalra S., et al. Barriers experienced by patients with multiple sclerosis in seeking care for lower urinary tract symptoms. Neurourology and Urodynamics. 2017;36(4):1208–1213. doi: 10.1002/nau.23101. - DOI - PubMed
    1. Khalaf K. M., Coyne K. S., Globe D. R., et al. The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis: Lower Urinary Tract Symptoms in MS Patients. Neurourology and Urodynamics. 2016;35(1):48–54. doi: 10.1002/nau.22670. - DOI - PubMed
    1. Hofmeester I., Kollen B. J., Steffens M. G., et al. Impact of the International Continence Society (ICS) report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review: Impact of the ICS-2002 report on standardisation of terminology in nocturia. BJU International. 2015;115(4):520–536. doi: 10.1111/bju.12753. - DOI - PubMed

LinkOut - more resources